The Filing Desk

Delcath Systems

DCTH · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

DCTH · Last close · November 13, 2026
$20.55
Value Delcath Systems yourself

Delcath Systems' revenue rose 129.1% to $85 million in fiscal 2025. Its operating margin was 0.8%, up from −33.4% a year earlier. Free cash flow was $21 million. It paid out $6 million in dividends and buybacks, 29% of free cash flow. The diluted share count rose 40.0%.

DELCATH SYSTEMS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-012019 Updated
Revenue
$85M
129.1%
Operating margin
0.8%
34.1 pts
Net income
$3M
 
Free cash flow
$21M
 
Return on capital
2.8%
 
Market cap
$843M
Nov 13 close
P/E
128.4x
On $0.16 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Delcath Systems does

Delcath Systems is an interventional oncology company, which means it treats cancer through procedures guided by imaging. It focuses on cancers in the liver, either starting there or spreading to it. Its lead product, the HEPZATO KIT, combines the chemotherapy drug melphalan with a device that delivers it directly to the liver. The FDA approved it in August 2023 for adults with a type of eye melanoma that has spread to the liver, and the first commercial use was in January 2024.

In Europe, the same delivery device is sold on its own as CHEMOSAT, without the drug. Delcath took over sales, marketing and distribution of CHEMOSAT there in March 2022. It reports one operating segment.

The company says it has limited experience as a commercial company and is trying to build revenue from HEPZATO. It has one melphalan supplier now and is in talks with others. It says it has stockpiled inventory and uses several suppliers for key parts to manage supply risk.

Its biggest risks, as it describes them

  • It has lost money since it started, and continuing losses could use up its capital.
  • It has limited experience selling products and may never be profitable if HEPZATO does not succeed.
  • It has an agreement with just one supplier of melphalan.
  • If it cannot make CHEMOSAT and HEPZATO successfully, it could not develop and sell them.
  • Product liability claims or recalls, and lawsuits, could hurt its business.
From Delcath Systems's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments238325391
Debt incl. finance leases5161000
Net debt (negative means net cash)−188−22−53−91
Net debt to EBITDA————−101.4x
Debt to equity0.4x—0.6x0.0x0.0x
Interest coverage−36.0x−18.1x−26.2x−10.0x—
Current ratio5.2x1.1x2.3x12.0x10.9x
Quick ratio5.0x1.0x2.1x10.9x10.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Delcath Systems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Delcath Systems says to expect

  • Full year 2026: revenueIncreases 2026 Revenue Guidance to a Range of $115 million to $117 million
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Delcath Systems reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 96 of 96 of 9
Rule of 40−1,540.2%1,650.0%153.7%
Altman Z''−45.05−8.721.26
Accruals ratio−58.2%−13.4%−19.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score4 of 96 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Delcath Systems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Delcath SystemsFY25129.1%0.8%24.6%2.8%−101.4x6
IRADIMEDFY2514.4%31.2%20.5%———Compare
CeribellFY2536.1%−65.6%−46.7%———Compare
Kestra Medical TechnologiesFY2659.0%−141.6%−122.6%——4Compare
Butterfly NetworkFY2519.0%−88.5%−16.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue23———4323785
Revenue growth14.0%36.3%————−23.5%−24.1%1,701.7%129.1%
Gross profit122113213173
Research and development8102010111419181429
Operating income−16−18−27−20−21−24−34−38−121
Net income−18−45−19−9−24−26−36−48−263
Diluted EPS (US$)−3,707.00−3,250.00−0.72−342.83−8.35−3.59−4.12−2.94−0.930.07
Diluted shares (millions)5142726379162840
Cash flow
Cash from operations−14−15−15−24−23−23−25−31−1922
Capital expenditure0000100012
Free cash flow−14−16−15−24−24−23−25−31−1921
Dividends paid0000000000
Share buybacks0000000006
Acquisitions0000000000
Stock-based compensation——————881024
Balance sheet at fiscal year end
Cash and short-term investments4421029238325391
Debt incl. finance leases——0205161000
Total assets3597143533183977124
Total liabilities378222113212423812
Shareholders' equity−21−15−62212−61669111
Margins and ratios
Gross margin72.4%74.2%———81.1%74.8%69.2%83.4%86.2%
Operating margin−825.3%−669.1%———−690.0%−1,245.0%−1,849.0%−33.4%0.8%
Net margin−902.2%−1,661.8%———−721.5%−1,342.7%−2,308.9%−70.9%3.2%
Free cash flow margin−726.5%−586.5%———−639.9%−925.3%−1,516.2%−51.7%24.6%
Rule of 40 (growth + FCF margin)−712.4%−550.1%————−948.8%−1,540.2%1,650.0%153.7%
Return on capital—————————2.8%
Return on equity−505.4%———−307.3%−150.7%−1,198.4%−961.4%−62.4%3.0%
Return on assets−70.5%−204.5%−244.4%−84.3%−98.9%−75.7%−143.2%−168.8%−45.8%2.7%
Net debt to EBITDA—————————−101.4x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Delcath Systems' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Delcath Systems.